Published in ACS Nano on April 28, 2016
An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat Commun (2016) 0.91
Nanomedicines for renal disease: current status and future applications. Nat Rev Nephrol (2016) 0.75
Nanomedicine Meets microRNA: Current Advances in RNA-Based Nanotherapies for Atherosclerosis. Arterioscler Thromb Vasc Biol (2016) 0.75
Targeted nanoparticles for colorectal cancer. Nanomedicine (Lond) (2016) 0.75
Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy. Am J Pathol (2017) 0.75
Traditional Chinese Medicine Protects against Cytokine Production as the Potential Immunosuppressive Agents in Atherosclerosis. J Immunol Res (2017) 0.75
Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 25.63
Macrophages in the pathogenesis of atherosclerosis. Cell (2011) 7.78
Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer (2003) 6.65
Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature (2007) 6.53
Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev (2006) 5.27
Resolution of inflammation: state of the art, definitions and terms. FASEB J (2007) 5.12
Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol (2009) 5.03
Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation (2007) 4.62
Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol (2005) 4.30
Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol (2005) 4.09
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A (2008) 3.80
Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science (2013) 3.64
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev (2013) 3.44
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev (2012) 3.34
Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol (2009) 3.32
A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol (2011) 3.14
Polymers for the sustained release of proteins and other macromolecules. Nature (1976) 2.81
Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J (2008) 2.78
Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol (1999) 2.73
Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe-/- mice. Arterioscler Thromb Vasc Biol (2008) 2.72
Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome. Am J Med (2011) 2.59
Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov (2014) 2.20
Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med (2015) 2.11
The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems--a review. Int J Pharm (2011) 2.02
Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity (2014) 1.85
Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov (2011) 1.78
Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res (2011) 1.71
Proinflammatory effects of IL-10 during human endotoxemia. J Immunol (2000) 1.69
IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression. J Biol Chem (2004) 1.65
Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci U S A (2010) 1.64
Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm (1998) 1.55
Cutting edge: Humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol (2011) 1.52
Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc Natl Acad Sci U S A (2013) 1.49
Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol (2012) 1.49
Pathology of the unstable plaque. Prog Cardiovasc Dis (2002) 1.41
Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut (2002) 1.41
Homeostasis, inflammation, and disease susceptibility. Cell (2015) 1.41
Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res (2014) 1.36
Neutrophils produce biologically active macrophage inflammatory protein-3alpha (MIP-3alpha)/CCL20 and MIP-3beta/CCL19. Eur J Immunol (2001) 1.33
Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc Natl Acad Sci U S A (2013) 1.27
Stat3 in resident macrophages as a repressor protein of inflammatory response. J Immunol (2005) 1.26
Pathways mediating resolution of inflammation: when enough is too much. J Pathol (2013) 1.24
Imaging and nanomedicine in inflammatory atherosclerosis. Sci Transl Med (2014) 1.23
Macrophage mitochondrial oxidative stress promotes atherosclerosis and nuclear factor-κB-mediated inflammation in macrophages. Circ Res (2013) 1.16
Local apoptosis mediates clearance of macrophages from resolving inflammation in mice. Blood (2013) 1.12
In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles. Proc Natl Acad Sci U S A (2011) 1.10
Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. Atherosclerosis (2005) 1.10
Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol (2015) 1.08
Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field? J Am Coll Cardiol (2015) 1.04
Stability of proteins encapsulated in injectable and biodegradable poly(lactide-co-glycolide)-glucose millicylinders. Int J Pharm (2008) 0.97
Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. ACS Nano (2013) 0.96
Reshaping the future of nanopharmaceuticals: ad iudicium. ACS Nano (2011) 0.95
Atherosclerosis - A matter of unresolved inflammation. Semin Immunol (2015) 0.94
Ultra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixer. ACS Nano (2014) 0.92
The role of tumor necrosis factor-α for interleukin-10 production by murine dendritic cells. Cell Immunol (2010) 0.84
Interleukin 10-coated nanoparticle systems compared for molecular imaging of atherosclerotic lesions. Int J Nanomedicine (2014) 0.82
Identification of potent small-molecule inhibitors of STAT3 with anti-inflammatory properties in RAW 264.7 macrophages. FEBS J (2012) 0.82
Interleukin-10: an anti-inflammatory marker to target atherosclerotic lesions via PEGylated liposomes. Mol Pharm (2012) 0.81
Natural progression of atherosclerosis from pathologic intimal thickening to late fibroatheroma in human coronary arteries: A pathology study. Atherosclerosis (2015) 0.81
A solvent-free thermosponge nanoparticle platform for efficient delivery of labile proteins. Nano Lett (2014) 0.76
(Re)solving atherosclerosis. Sci Transl Med (2015) 0.76